• 24 Tech Roqad st Ny 10023
  • editech@mail.com
Menu
  • Newsroom
  • Newsroom
  • Office Hour : 08:00am - 6:00pm
Facebook Twitter Google-plus Instagram
logo
  • About Us
    • About Cohance
    • Purpose, Values & Promise
    • Leadership
    • Sustainability
    • Quality, Regulatory & Compliance
    • Science & Technology
  • Small Molecule API
    • API Development
    • API Manufacturing
  • ADCs
    • Integrated CRDMO
    • ADC Payloads
  • Nucleic Acid Chemistry
    • Nucleosides & Phosphoramidites Development
    • Nucleosides & Phosphoramidites Manufacturing
    • Products
  • Generic APIs
    • Product List
  • Specialty Chemicals
    • Agrochemicals
  • Investors
    • Financial Info
    • Shareholder Info
    • Corporate Governance
    • Corporate Info
    • Disclosure under Reg 46 of SEBI LODR
  • Global Presence
  • Events
  • Careers
  • Get In Touch
  • About Us
    • About Cohance
    • Purpose, Values & Promise
    • Leadership
    • Sustainability
    • Quality, Regulatory & Compliance
    • Science & Technology
  • Small Molecule API
    • API Development
    • API Manufacturing
  • ADCs
    • Integrated CRDMO
    • ADC Payloads
  • Nucleic Acid Chemistry
    • Nucleosides & Phosphoramidites Development
    • Nucleosides & Phosphoramidites Manufacturing
    • Products
  • Generic APIs
    • Product List
  • Specialty Chemicals
    • Agrochemicals
  • Investors
    • Financial Info
    • Shareholder Info
    • Corporate Governance
    • Corporate Info
    • Disclosure under Reg 46 of SEBI LODR
  • Global Presence
  • Events
  • Careers
  • Get In Touch

Have Any Questions?

+ 84 1800 688 900

Close
Contact Us

Press Releases

Cohance :Press Releases
  • In The News
  • Press Releases
  • Events

This is the heading

VIEW DETAILS

This is the heading

View Details

This is the heading

View Details

This is the heading

View Details

This is the heading

View Details
Show More

This is the heading

VIEW DETAILS

This is the heading

VIEW DETAILS

This is the heading

VIEW DETAILS
  • In The News
  • Press Releases
  • Events
press-release
29th July 2025

Cohance Lifesciences Appoints Yann D'Herve as CEO of CDMO Business

VIEW DETAILS

7th May 2025

Press Release regarding change in name of the Company ...
VIEW DETAILS →
press-release
7th May 2025

Press Release regarding change in name of the Company

VIEW DETAILS

25th April 2025

Press Release – Effective date for Scheme of Amalgamation ...
VIEW DETAILS →

7th March 2025

US FDA completes surveillance inspection of Cohance Life Sciences’ API ...
VIEW DETAILS →
press-release
25th April 2025

Press Release – Effective date for Scheme of Amalgamation

VIEW DETAILS
press-release
7th March 2025

US FDA completes surveillance inspection of Cohance Life Sciences’ API ...

VIEW DETAILS

7th December 2024

Suven to acquire controlling stake in NJ Bio, Inc., an ADC specialist ...
VIEW DETAILS →
press-release
7th December 2024

Suven to acquire controlling stake in NJ Bio, Inc., an ADC specialist ...

VIEW DETAILS

19th September 2024

Suven Pharmaceuticals names Mr. Vivek Sharma as ExecutiveChairman ...
VIEW DETAILS →
press-release
19th September 2024

Suven Pharmaceuticals names Mr. Vivek Sharma as ExecutiveChairman ...

VIEW DETAILS

9th August 2024

Suven Pharmaceuticals announces Q1 FY25 financial results ...
VIEW DETAILS →
press-release
9th August 2024

Suven Pharmaceuticals announces Q1 FY25 financial results ...

VIEW DETAILS

13th June 2024

Suven to acquire a majority stake in an oligonucleotide focused ...
VIEW DETAILS →

30th May 2024

Suven Pharmaceuticals Announces Full-Year FY24 Results ....
VIEW DETAILS →
press-release
13th June 2024

Suven to acquire a majority stake in an oligonucleotide focused ...

VIEW DETAILS
Show More
press-release
30th May 2024

Suven Pharmaceuticals Announces Full-Year FY24 Results ....

VIEW DETAILS
press-release
5th February 2024

Suven Pharma reports FY24 third quarter and nine months financial results ...

VIEW DETAILS
press-release
29th February 2024

Suven Announces Merger of Cohance Lifesciences, Forging ...

VIEW DETAILS
press-release
2024

Suven Pharma reports FY24 second quarter and half yearly financial results ...

VIEW DETAILS
  • White Papers
  • Case Studies
  • Blogs
  • Videos
Policies
  • Code of Conduct under SEBI Insider Trading Regulations
  • Prohibition of Insider Trading Policy
  • Code of Practices Procedures for fair disclosure of UPSI
  • Remuneration Policy
  • Policy for Archival of Documents and Information
  • Policy for Determining Material Event or Information
  • Policy for Determining Material Subsidiaries
  • Policy on Related Party Transactions
  • Whistle Blower Policy
  • Anti-bribery and Anti-corruption policy
  • Dividend Distribution Policy
Committee Charters
  • Audit Committee Charter
  • Nomination and Remuneration Committee Charter
  • Stakeholders Relationship Committee Charter
  • Risk Management Committee Charter
  • Corporate Social Responsibility Committee Charter
  • Investment, Banking and Authorisations Committee Charter
cropped-mid-section-unrecognizable-woman-signing-document_1098-18908

Terms & Conditions of
appointment of ID's

Committees of Board and Criteria of making payment to NEDs

Code of Conduct

NoPath-Copy-4

Directors Familiarization Programs

Error: Contact form not found.

About

  • About Cohance
  • Purpose, Values & Promise
  • Leadership
  • Sustainability
  • Quality, Regulatory
    & Compliance
  • Science & Technology

Small Molecule API

  • API Development
  • API Manufacturing

ADCs

  • Integrated CRDMO
  • ADC Payloads

Nucleic Acid Chemistry

  • Nucleosides &
    Phosphoramidites
    Development
  • Nucleosides &
    Phosphoramidites
    Manufacturing
  • Products

Generic APIs

  • Product List

Specialty Chemicals

  • Agro Chemicals

Investors

  • Financial Info
  • Shareholder Info
  • Corporate Governance
  • Corporate Info
  • Disclosure under
    Reg 46 of SEBI LODR

Resources

  • News
  • Brochures
  • Whitepapers
  • Videos

Follow Us

Linkedin
  • Terms Of Use
  • Privacy Policy
Copyright © 2025.     logo
  • Home
  • About
  • Pharma CDMO
  • API+
  • Specialty Chemicals
  • Investor Relations
Top